Fenoﬁbrate suppresses cellular metabolic memory of high glucose in diabetic retinopathy via a sirtuin 1-dependent signalling pathway

Zhao,Shuzhi; Li,Jun; Wang,Na; Zheng,Bingqing; Li,Tao; Gu,Qing; Xu,Xun; Zheng,Zhi

doi:10.3892/mmr.2015.4164

Fenoﬁbrate suppresses cellular metabolic memory of high glucose in diabetic retinopathy via a sirtuin 1-dependent signalling pathway

Authors:
- Shuzhi Zhao
- Jun Li
- Na Wang
- Bingqing Zheng
- Tao Li
- Qing Gu
- Xun Xu
- Zhi Zheng
View Affiliations

Affiliations: Department of Ophthalmology, First People's Hospital of Shanghai, Shanghai Jiaotong University, Shanghai 200080, P.R. China, Department of Ophthalmology, Lishui City Center Hospital, Lishui, Zhejiang 323000, P.R. China
Published online on: July 31, 2015 https://doi.org/10.3892/mmr.2015.4164
Pages: 6112-6118

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Inﬂammation is a major contributing factor in the development of diabetic microvascular complications, regardless of whether improved glycaemic control is achieved. Studies have increasingly indicated that fenoﬁbrate, a lipid‑lowering therapeutic agent in clinical use, exerts a potential anti‑inﬂammatory effect, which is mediated by sirtuin 1 (SIRT1; an NAD+‑dependent deacetylase) in endothelial cells. The aim of the present study was to investigate the inhibitory effect of fenoﬁbrate on metabolic memory (via the regulation of SIRT1), and inflammatory responses in cell and animal models of diabetic retinopathy (DR). The data demonstrated that high glucose treatment in human retinal endothelial cells (HRECs) inhibited the expression and deacetylase activity of SIRT1. The reduction of SIRT1 expression and deacetylase activity persisted following a return to normal glucose levels. Furthermore, nuclear factor‑κB expression was observed to be negatively correlated with SIRT1 expression and activity in HRECs under high glucose levels and the subsequent return to normal glucose levels. Fenoﬁbrate treatment abrogated these changes. Knockdown of SIRT1 attenuated the effect of fenoﬁbrate on high glucose‑induced NF‑κB expression. In addition, fenoﬁbrate upregulated SIRT1 expression through peroxisome proliferator‑activated receptor α in high glucose‑induced metabolic memory. These findings indicate that fenoﬁbrate is important in anti‑inflammatory processes and suppresses the cellular metabolic memory of high glucose‑induced stress via the SIRT1‑dependent signalling pathway. Thus, treatment with fenofibrate may offer a promising therapeutic strategy for halting the development of DR and other complications of diabetes.

View Figures

View References

1	Lutty GA: Effects of diabetes on the eye. Invest Ophthalmol Vis Sci. 54:ORSF81–87. 2013. View Article : Google Scholar : PubMed/NCBI
2	No authors listed. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med. 342:381–389. 2000. View Article : Google Scholar : PubMed/NCBI
3	Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 287:2563–2569. 2002. View Article : Google Scholar : PubMed/NCBI
4	Ceriello A, Ihnat MA and Thorpe JE: Clinical review 2: The 'metabolic memory': is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab. 94:410–415. 2009. View Article : Google Scholar
5	Zheng Z, Chen H, Li J, Li T, Zheng B, Zheng Y, Jin H, He Y, Gu Q and Xu X: Sirtuin 1-mediated cellular metabolic memory of high glucose via the LKB1/AMPK/ROS pathway and therapeutic effects of metformin. Diabetes. 61:217–228. 2012. View Article : Google Scholar :
6	Kowluru RA and Chan PS: Metabolic memory in diabetes - from in vitro oddity to in vivo problem: Role of apoptosis. Brain Res Bull. 81:297–302. 2010. View Article : Google Scholar
7	Kowluru RA, Chakrabarti S and Chen S: Re-institution of good metabolic control in diabetic rats and activation of caspase-3 and nuclear transcriptional factor (NF-kappaB) in the retina. Acta Diabetol. 41:194–199. 2004. View Article : Google Scholar
8	Kowluru RA, Zhong Q and Kanwar M: Metabolic memory and diabetic retinopathy: Role of inflammatory mediators in retinal pericytes. Exp Eye Res. 90:617–623. 2010. View Article : Google Scholar : PubMed/NCBI
9	Sen R and Baltimore D: Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell. 47:921–928. 1986. View Article : Google Scholar : PubMed/NCBI
10	Oeckinghaus A and Ghosh S: The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol. 1:a0000342009. View Article : Google Scholar
11	DiDonato JA, Mercurio F and Karin M: NF-kappaB and the link between inflammation and cancer. Immunol Rev. 246:379–400. 2012. View Article : Google Scholar : PubMed/NCBI
12	Kowluru RA, Koppolu P, Chakrabarti S and Chen S: Diabetes-induced activation of nuclear transcriptional factor in the retina and its inhibition by antioxidants. Free Radic Res. 37:1169–1180. 2003. View Article : Google Scholar
13	Yu J and Auwerx J: Protein deacetylation by SIRT1: An emerging key post-translational modification in metabolic regulation. Pharmacol Res. 62:35–41. 2010. View Article : Google Scholar
14	Haigis MC and Sinclair DA: Mammalian sirtuins: Biological insights and disease relevance. Annu Rev Pathol. 5:253–295. 2010. View Article : Google Scholar : PubMed/NCBI
15	Baur JA: Resveratrol, sirtuins and the promise of a DR mimetic. Mech Ageing Dev. 131:261–269. 2010. View Article : Google Scholar : PubMed/NCBI
16	Cai W, Ramdas M, Zhu L, Chen X, Striker GE and Vlassara H: Oral advanced glycation endproducts (AGEs) promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and sirtuin 1. Proc Natl Acad Sci USA. 109:15888–15893. 2012. View Article : Google Scholar : PubMed/NCBI
17	Tsai KL, Huang PH, Kao CL, Leu HB, Cheng YH, Liao YW, Yang YP, Chien Y, Wang CY, Hsiao CY, et al: Aspirin attenuates vinorelbine-induced endothelial inflammation via modulating SIRT1/AMPK axis. Biochem Pharmacol. 88:189–200. 2014. View Article : Google Scholar
18	Kim ES, Isoda F, Kurland I and Mobbs CV: Glucose-induced metabolic memory in Schwann cells: prevention by PPAR agonists. Endocrinology. 154:3054–3066. 2013. View Article : Google Scholar : PubMed/NCBI
19	Wang W, Bai L, Qiao H, Lu Y, Yang L, Zhang J, Lin R, Ren F, Zhang J and Ji M: The protective effect of fenofibrate against TNF-α-induced CD40 expression through SIRT1-mediated deacetylation of NF-κB in endothelial cells. Inflammation. 37:177–185. 2014. View Article : Google Scholar
20	Wang W, Lin Q, Lin R, Zhang J, Ren F, Zhang J, Ji M and Li Y: PPARalpha agonist fenofibrate attenuates TNF-α-induced CD40 expression in 3T3-L1 adipocytes via the SIRT1-dependent signaling pathway. Exp Cell Res. 319:1523–1533. 2013. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
22	No authors listed. The effect of intensive diabetes therapy on the development and progression of neuropathy. The Diabetes Control and Complications Trial Research Group. Ann Intern Med. 122:561–568. 1995. View Article : Google Scholar : PubMed/NCBI
23	Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA. 290:2159–2167. 2003. View Article : Google Scholar : PubMed/NCBI
24	Ihnat MA, Thorpe JE and Ceriello A: Hypothesis: The 'metabolic memory', the new challenge of diabetes. Diabet Med. 24:582–586. 2007. View Article : Google Scholar : PubMed/NCBI
25	LeRoith D, Fonseca V and Vinik A: Metabolic memory in diabetes-focus on insulin. Diabetes Metab Res Rev. 21:85–90. 2005. View Article : Google Scholar
26	Baker RG, Hayden MS and Ghosh S: NF-κB, inflammation and metabolic disease. Cell Metab. 13:11–22. 2011. View Article : Google Scholar : PubMed/NCBI
27	Salminen A, Kauppinen A, Suuronen T and Kaarniranta K: SIRT1 longevity factor suppresses NF-kappaB-driven immune responses: Regulation of aging via NF-kappaB acetylation? Bioessays. 30:939–942. 2008. View Article : Google Scholar : PubMed/NCBI
28	Yao H and Rahman I: Perspectives on translational and therapeutic aspects of SIRT1 in inflammaging and senescence. Biochem Pharmacol. 84:1332–1339. 2012. View Article : Google Scholar : PubMed/NCBI
29	Xie J, Zhang X and Zhang L: Negative regulation of inflammation by SIRT1. Pharmacol Res. 67:60–67. 2013. View Article : Google Scholar
30	Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS, Taskinen MR, Simes RJ, Tse D, Williamson E, et al: Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): A randomised controlled trial. Lancet. 370:1687–1697. 2007. View Article : Google Scholar : PubMed/NCBI
31	Ginsberg HN, Elam MB, Lovato LC III, Crouse JR III, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, et al: Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 362:1563–1574. 2010. View Article : Google Scholar : PubMed/NCBI
32	Planavila A, Iglesias R, Giralt M and Villarroya F: Sirt1 acts in association with PPARalpha to protect the heart from hypertrophy, metabolic dysregulation and inflammation. Cardiovasc Res. 90:276–284. 2011. View Article : Google Scholar
33	Biscetti F, Gaetani E, Flex A, Aprahamian T, Hopkins T, Straface G, Pecorini G, Stigliano E, Smith RC, Angelini F, et al: Selective activation of peroxisome proliferator-activated receptor (PPAR)alpha and PPAR gamma induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism. Diabetes. 57:1394–1404. 2008. View Article : Google Scholar : PubMed/NCBI
34	Okayasu T, Tomizawa A, Suzuki K, Manaka K and Hattori Y: PPARalpha activators upregulate eNOS activity and inhibit cytokine-induced NF-kappaB activation through AMP-activated protein kinase activation. Life Sci. 82:884–891. 2008. View Article : Google Scholar : PubMed/NCBI
35	Shen W, Gao Y, Lu B, Zhang Q, Hu Y and Chen Y: Negatively regulating TLR4/NF-kappaB signaling via PPARα in endotoxin-induced uveitis. Biochim Biophys Acta. 1842:1109–1120. 2014. View Article : Google Scholar : PubMed/NCBI